CytoSorb® therapy: a new approach to treat critically ill patients with COVID-19 – a retrospective study
Objective: The Coronavirus 2019 (COVID-19) pandemic has resulted in significant mortality and morbidity. Patients with severe COVID-19 infection experience cytokine storm that makes the treatment approach more challenging. The aim of the present study was to evaluate the effects of CytoSorb® therapy...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Verduci Editore
2023-06-01
|
| Series: | International Journal of Medical Device and Adjuvant Treatments |
| Subjects: | |
| Online Access: | https://www.ijmdat.com/wp-content/uploads/sites/3/2023/06/e401.pdf |
| _version_ | 1827915615324602368 |
|---|---|
| author | K. Patil M. Priyadarsini |
| author_facet | K. Patil M. Priyadarsini |
| author_sort | K. Patil |
| collection | DOAJ |
| description | Objective: The Coronavirus 2019 (COVID-19) pandemic has resulted in significant mortality and morbidity. Patients with severe COVID-19 infection experience cytokine storm that makes the treatment approach more challenging. The aim of the present study was to evaluate the effects of CytoSorb® therapy in COVID-19 patients admitted in ICU.
Patients and Methods: This was a single-center, retrospective study conducted at Sunshine Hospital, Hyderabad, India from January 2020 to November 2020. Patients diagnosed with COVID-19 along with signs of sepsis and with a minimum of one organ dysfunction were enrolled in the study. All the patients were treated with CytoSorb® therapy. Clinical and laboratory parameters such as procalcitonin (PCT), serum lactate, interleukin-6 (IL-6), mean arterial pressure (MAP), C-Reactive Protein and the patients’ length of stay in intensive care were measured.
Results: A total of 20 patients were enrolled in this study; of these 13 patients (65%) survived. One patient left against medical advice and was thus excluded from the analysis. Post CytoSorb® therapy, a reduction in the levels of PCT, total leucocyte count (TLC), and platelet count in the survivor group was reported. The dosage of norepinephrine decreased by 46% in the survivor group but decreased by 0.8% in the non-survivor group (p= 0.0424 for survivor vs. non survivors). The average number of days spent by all patients in ICU was 9±5.25.
Conclusions: The use of CytoSorb® therapy for patients with COVID-19 is a safe and effective treatment option when initiated in a timely manner. |
| first_indexed | 2024-03-13T03:01:21Z |
| format | Article |
| id | doaj.art-237e8621ad8f4c9bad4d3fb4c96f30c8 |
| institution | Directory Open Access Journal |
| issn | 2476-0994 |
| language | English |
| last_indexed | 2024-03-13T03:01:21Z |
| publishDate | 2023-06-01 |
| publisher | Verduci Editore |
| record_format | Article |
| series | International Journal of Medical Device and Adjuvant Treatments |
| spelling | doaj.art-237e8621ad8f4c9bad4d3fb4c96f30c82023-06-27T12:11:05ZengVerduci EditoreInternational Journal of Medical Device and Adjuvant Treatments2476-09942023-06-01610.32113/ijmdat_20236_401401CytoSorb® therapy: a new approach to treat critically ill patients with COVID-19 – a retrospective studyK. Patil0M. Priyadarsini1Department of Nephrology, Sunshine Hospital and Renown Clinical Services, Hyderabad, IndiaDepartment of Critical Care, Sunshine Hospital, Gachibowli, Hyderabad, IndiaObjective: The Coronavirus 2019 (COVID-19) pandemic has resulted in significant mortality and morbidity. Patients with severe COVID-19 infection experience cytokine storm that makes the treatment approach more challenging. The aim of the present study was to evaluate the effects of CytoSorb® therapy in COVID-19 patients admitted in ICU. Patients and Methods: This was a single-center, retrospective study conducted at Sunshine Hospital, Hyderabad, India from January 2020 to November 2020. Patients diagnosed with COVID-19 along with signs of sepsis and with a minimum of one organ dysfunction were enrolled in the study. All the patients were treated with CytoSorb® therapy. Clinical and laboratory parameters such as procalcitonin (PCT), serum lactate, interleukin-6 (IL-6), mean arterial pressure (MAP), C-Reactive Protein and the patients’ length of stay in intensive care were measured. Results: A total of 20 patients were enrolled in this study; of these 13 patients (65%) survived. One patient left against medical advice and was thus excluded from the analysis. Post CytoSorb® therapy, a reduction in the levels of PCT, total leucocyte count (TLC), and platelet count in the survivor group was reported. The dosage of norepinephrine decreased by 46% in the survivor group but decreased by 0.8% in the non-survivor group (p= 0.0424 for survivor vs. non survivors). The average number of days spent by all patients in ICU was 9±5.25. Conclusions: The use of CytoSorb® therapy for patients with COVID-19 is a safe and effective treatment option when initiated in a timely manner.https://www.ijmdat.com/wp-content/uploads/sites/3/2023/06/e401.pdfcytokinescovid-19sepsishemoadsorptionacute respiratory distress syndromecoronaviruscytosorb® |
| spellingShingle | K. Patil M. Priyadarsini CytoSorb® therapy: a new approach to treat critically ill patients with COVID-19 – a retrospective study International Journal of Medical Device and Adjuvant Treatments cytokines covid-19 sepsis hemoadsorption acute respiratory distress syndrome coronavirus cytosorb® |
| title | CytoSorb® therapy: a new approach to treat critically ill patients with COVID-19 – a retrospective study |
| title_full | CytoSorb® therapy: a new approach to treat critically ill patients with COVID-19 – a retrospective study |
| title_fullStr | CytoSorb® therapy: a new approach to treat critically ill patients with COVID-19 – a retrospective study |
| title_full_unstemmed | CytoSorb® therapy: a new approach to treat critically ill patients with COVID-19 – a retrospective study |
| title_short | CytoSorb® therapy: a new approach to treat critically ill patients with COVID-19 – a retrospective study |
| title_sort | cytosorb r therapy a new approach to treat critically ill patients with covid 19 a retrospective study |
| topic | cytokines covid-19 sepsis hemoadsorption acute respiratory distress syndrome coronavirus cytosorb® |
| url | https://www.ijmdat.com/wp-content/uploads/sites/3/2023/06/e401.pdf |
| work_keys_str_mv | AT kpatil cytosorbtherapyanewapproachtotreatcriticallyillpatientswithcovid19aretrospectivestudy AT mpriyadarsini cytosorbtherapyanewapproachtotreatcriticallyillpatientswithcovid19aretrospectivestudy |